[Cardiovascular drugs and diabetes].
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001337:Autonomic Agents / Q000494:pharmacology; D002110:Caffeine / Q000494:pharmacology; D002199:Capillary Permeability / Q000187:drug effects; D002200:Capillary Resistance / Q000187:drug effects; D050260:Carbohydrate Metabolism; D002301:Cardiac Glycosides / Q000494:pharmacology*; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D003911:Dextrans / Q000494:pharmacology; D003920:Diabetes Mellitus / Q000378:metabolism / Q000503:physiopathology*; D004285:Dogs; D005934:Glucagon / Q000502:physiology; D005958:Glucosephosphates / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007328:Insulin / Q000502:physiology; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D010085:Oxidative Phosphorylation / Q000187:drug effects; D010101:Oxygen Consumption / Q000187:drug effects; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D013565:Sympatholytics / Q000494:pharmacology; D013566:Sympathomimetics / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D001337:Autonomic Agents; D002301:Cardiac Glycosides; D000697:Central Nervous System Stimulants; D003911:Dextrans; D005958:Glucosephosphates; D007328:Insulin; D008996:Monoamine Oxidase Inhibitors; D013565:Sympatholytics; D013566:Sympathomimetics; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D002110:Caffeine; D005934:Glucagon; D011433:Propranolol
Médications cardio-vasculaires et diabète.